This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Hormones Medicine Protein 
Scienmag
JUNE 27, 2022
Hormone therapy is successful at keeping metastatic prostate cancer under control, but eventually the tumor cells become resistant to it. An unexpected potential solution has now emerged in medicines not designed to fight cancer, but to target proteins that regulate a cell’s circadian rhythm.
91 
Scienmag
SEPTEMBER 22, 2020
Brazilian researchers observed that in uninfected adipocytes, the hormone irisin altered the expression of genes that regulate ACE-2, which encodes a protein to which the virus binds in order to invade human cells.
97 This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 15, 2022
The UK National Institute for Health and Care Excellence (NICE) has recommended Novartis Pharmaceuticals UK’s Piqray (alpelisib) along with hormonal therapy fulvestrant to treat hormone receptor+, HER2-, PIK3CA-mutated locally advanced or metastatic breast cancer.
147 
Scienmag
APRIL 22, 2021
Notch proteins are key regulators of growth and differentiation of both normal and cancer cells. These results can be used in the development of new cancer treatments, especially for hormone-dependent breast cancer.
75 
Camargo
NOVEMBER 29, 2021
The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Recombinant therapeutic proteins. Fusion proteins. Gene and cellular therapies. Growth factors. Interferons.
180 
Pharmaceutical Technology
SEPTEMBER 26, 2022
The 'life-extending' drug combination is recommended for usage in adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer who have previously received hormone therapy. It acts by hindering proteins in cancer cells to avert cell division and growth.
130 
Medical Xpress
DECEMBER 12, 2022
Ana Guadaño at the Alberto Sols Biomedical Research Institute (IIBM, a combined CSIC-UAM center) and involving the Complutense University of Madrid (UCM), used CRISPR gene editing techniques to incorporate into mice a mutation of the MCT8 protein responsible for transporting thyroid hormones to the interior of the cell.
69 
XTalks
NOVEMBER 26, 2020
In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. The study was published in the journal PLOS Biology. Related: Can Vitamin D Be Beneficial for COVID-19 Patients?
98 
Pharmaceutical Technology
MAY 31, 2023
The therapeutic candidate targets immune checkpoint, programmed cell death protein 1 (PD1). The company’s portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders, and others.
100 
Scienmag
SEPTEMBER 15, 2020
Researchers develop a wider spectrum for dLight1 sensor, allowing multiplex imaging of neurotransmitters Credit: UC Regents Sacramento, CA– In 2018, Lin Tian and her team at UC Davis Health developed dLight1, a single fluorescent protein-based biosensor.
55 
Pharmaceutical Technology
FEBRUARY 14, 2023
Alkaloids, natural dyes, drugs, proteins, and enzymes are some of the important classes of natural heterocyclic compounds essential for human life. The company filed heterocyclic composition patents in areas such as PAD4 inhibitors, factor Xa inhibitors, and nuclear hormone receptor modulators.
130 
The Pharma Data
JUNE 26, 2021
Basel, June 23, 2021 — VISION data published today in The New England Journal of Medicine (NEJM) shows that 177 Lu-PSMA-617 plus standard of care (SOC) significantly improved both overall survival (HR = 0.62 [95% CI: 0.52?0.74]; 0.74]; P<0.001; median 15.3 months) and imaging-based progression-free survival (HR = 0.40 [99.2%
52 
The Pharma Data
DECEMBER 9, 2020
The trial, conducted in nine countries, found that adding chemotherapy to hormone-blocking drugs brought no added benefit to a particular group of patients. Those were postmenopausal women with hormone-sensitive breast cancer that had spread to only one to three lymph nodes, and who had a low risk of recurrence. WEDNESDAY, Dec.
52 
Delveinsight
JULY 30, 2020
Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. The disorder can occur at any stage of life and vary with severity.
52 
The Pharma Data
JANUARY 7, 2021
However, Sanofi’s programs have significant depth below the waterline that could result in the approval of important medicines to treat difficult diseases. He also noted innovations are occurring with protein degraders, antibody conjugates, nanobodies and multi-specific antibodies, specifically bi- and tri-specific.
52 
Pfizer
AUGUST 15, 2022
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. Contraception : Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. COVID-19, Vaccines.
99 
XTalks
FEBRUARY 7, 2023
Current treatments for HR+ breast cancer patients include hormonal therapies, chemotherapies for those that do not respond to hormonal therapy alone and targeted therapies, either stand-alone or in combination with hormonal therapies. What does this Approval Mean for Breast Cancer Patients?
52 
The Pharma Data
MARCH 22, 2021
These groundbreaking data confirm our belief in the potential of 177 Lu-PSMA-617 to reimagine outcomes for these patients through phenotypic precision medicine. We would not be able to realize our commitment to reimagining medicine without the partnership of patients and their families.”.
52 
Roots Analysis
OCTOBER 24, 2023
Owing to the advancement in clinical pharmacology and oncology domain, and the rising demand for targeted therapeutics and precision medicines, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become one of the key areas of interest to researchers and drug manufacturers across the globe.
Pfizer
DECEMBER 13, 2022
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. COVID-19 Medicines.
110 
Pfizer
JANUARY 27, 2023
Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives.
112 
The Pharma Data
AUGUST 6, 2020
Safety for the Tecentriq combination appeared to be consistent with the known safety profile of the individual medicines, and no new safety signals were identified. This includes studies evaluating Tecentriq both alone and in combination with other medicines. By inhibiting PD-L1, Tecentriq may enable the activation of T-cells.
52 
The Pharma Data
APRIL 27, 2022
The Food and Drug Administration’s (FDA) BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. 1-4 Low HER2 expression occurs in both HR-positive and HR-negative disease.
52 
XTalks
JUNE 10, 2024
Efruxifermin is a novel Fc-FGF21 fusion protein designed to emulate the activity of native FGF21, an endogenous hormone that regulates metabolism and alleviates cellular stress. It can lead to inflammation, fibrosis, cirrhosis, liver failure and potentially death.
52 
The Pharma Data
AUGUST 30, 2021
TNBC remains the most challenging type of breast cancer to treat, which makes the decision to withdraw so difficult for us, as patients have had this medicine as an important option for more than two years,” said Levi Garraway, M.D., This is not related to any changes in either the efficacy or safety associated with Tecentriq. receptors.
52 
The Pharma Data
SEPTEMBER 16, 2020
Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating Gavreto TM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer. Gavreto is being jointly commercialised by Genentech, a wholly owned member of the Roche Group, and Blueprint Medicines in the U.S.
52 
Pfizer
JANUARY 27, 2023
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.
75 
The Pharma Data
JANUARY 27, 2021
These include in-vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities.
52 
The Pharma Data
MAY 14, 2021
Metabolic Breakthrough Rebalances Your “Hot Zone Hormones” So Any Woman Over 35 Can Blast Off Belly Fat, Shape Flabby Muscle And See Your Most Attractive,Youthful, And Energized Body Ever In Only 30 Days WITHOUT Suffering Through Restrictive Diets Or Trying To Starve Yourself Skinny. Helping you Permanently Blast off Belly Fat.
52 
XTalks
DECEMBER 22, 2021
RNA, and its protein-generating form messenger RNA (mRNA) discovered in 1961 , has quickly transitioned from being an obscure, finicky molecule that is difficult to work with, to becoming a significant cornerstone of therapeutic innovation in pharma and biotech. The RNA Revolution: From mRNA Vaccines to RNA Editing.
98 
The Pharma Data
APRIL 7, 2023
The safety and tolerability of these combinations are broadly consistent with that observed in prior clinical trials and the known profiles of the individual medicines. The companies develop Lynparza in combination with their respective PD-L1 and PD-1 medicines independently. Source link: [link]
40 
Pfizer
DECEMBER 20, 2022
The extension of the NDA review period will not impact the Emergency Use Authorization (EUA) or the current availability of the medicine for eligible patients. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. In the U.S., approximately 7.6
69 
The Pharma Data
APRIL 27, 2021
The FDA’s Accelerated Approval Program allows for conditional approval of a medicine that fills an unmet medical need for a serious condition, with specific postmarketing requirements (PMRs) to confirm the clinical benefit and convert to regular approval. receptors.
40 
Roots Analysis
JANUARY 23, 2024
They also play important roles in antibiotics , toxins, hormones, and enzymes. These versatile molecules serve various diverse roles, functioning as neurotransmitters, growth factors, ion channel ligands, hormones, anti-infectives, and more. When introduced into the body, lab-synthesized peptides become active.
40 
Velocity Clinical Research
JUNE 27, 2023
The prolific researchers also had findings simultaneously published in the New England Journal of Medicine and The Lancet. “It’s a chemical, a small molecule that also acts on the GLP-1 receptor, but because it’s not a protein it’s not degraded by enzymes,” said Dr. Frias.
52 
The Pharma Data
SEPTEMBER 19, 2020
This includes studies evaluating Tecentriq both alone and in combination with other medicines. Our medicines, along with companion diagnostic tests, have contributed to bringing breakthrough innovations in HER2-positive and triple negative breast cancers. By inhibiting PD-L1, Tecentriq may enable the activation of T-cells.
52 
The Pharma Data
MAY 15, 2021
Page 311 – Knowing how keeping your body’s PH level normalized is your key to preventing most diseases (cardiovascular, diabetes, cancer, hormone imbalance, immune deficiency, kidney problems, headaches, etc.). Learn a simple method to test your body’s PH level and how you can easily keep it within safe levels.
52 
The Pharma Data
JUNE 18, 2021
deputy head of hematology, University of Amsterdam Faculty of Medicine. The BTK protein sends important signals that tell B cells to mature and produce antibodies. IMBRUVICA is the only FDA-approved medicine in WM and cGVHD. VENCLXEXTA/VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.
52 
The Pharma Data
FEBRUARY 8, 2021
Metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer (mHSPC), refers to prostate cancer that still responds to hormonal therapy and has spread beyond the prostate to other parts of the body. [4]. New England Journal of Medicine. About ERLEADA ® (apalutamide). 3] Chi, K.
52 
The Pharma Data
JANUARY 10, 2021
We expect to further advance our late stage endocrinology pipeline with the anticipated approval and launch in the United States and the approval in Europe of TransCon hGH for pediatric growth hormone deficiency, and to obtain phase 3 results for TransCon PTH in adult hypoparathyroidism. ?. . .
40 
The Pharma Data
JUNE 18, 2021
The BTK protein sends important signals that tell B cells to mature and produce antibodies. IMBRUVICA is the only FDA-approved medicine in WM and cGVHD. IMBRUVICA was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway. with certain other medicines may affect how IMBRUVICA ® ?works
40 
The Pharma Data
MAY 15, 2021
SLIM OVER 55 is THE ONLY program for women over 55 that is especially designed for your body who has gone through menopause and needs to get all the hormones back in balance! Each of the Slim Over 55 meals are perfectly balanced with precise nutrients, carbohydrates, proteins, vitamins and the healthiest of fats.
52 
The Pharma Data
JUNE 18, 2021
lead study investigator of the Phase 3 RESONATE-2 trial, and Professor of Medicine at the Wilmot Cancer Institute, University of Rochester. The BTK protein sends important signals that tell B cells to mature and produce antibodies. IMBRUVICA ® is the only FDA-approved medicine in WM and cGVHD. Barr , M.D., Taking IMBRUVICA ® ?with
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content